Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's receivables is $130M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), GERM shows a receivables of $130M. That compares with $740M in the prior-year period — down 82.1% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, GERM's receivables is now $130M (was $740M) — a 82.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF is outperforming or lagging.
Tracking GERM's receivables over time shows whether Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF is scaling, shrinking, or reshaping that part of the business. The current reading is $130M That compares with $740M in the prior-year period — down 82.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this receivables page, Stockcircle has Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $130M) with ownership activity and broader fundamentals.